Rapamycin Prevents the Development and Progression of Mutant Epidermal Growth Factor Receptor Lung Tumors with the Acquired Resistance Mutation T790M

Shigeru Kawabata, José R. Mercado-Matos, M. Christine Hollander, Danielle Donahue, Willie Wilson, Lucia Regales, Mohit Butaney, William Pao, Kwok Kin Wong, Pasi A. Jänne, Phillip A. Dennis

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Lung cancer in never-smokers is an important disease often characterized by mutations in epidermal growth factor receptor (EGFR), yet risk reduction measures and effective chemopreventive strategies have not been established. We identify mammalian target of rapamycin (mTOR) as potentially valuable target for EGFR mutant lung cancer. mTOR is activated in human lung cancers with EGFR mutations, and this increases with acquisition of T790M mutation. In a mouse model of EGFR mutant lung cancer, mTOR activation is an early event. As a single agent, the mTOR inhibitor rapamycin prevents tumor development, prolongs overall survival, and improves outcomes after treatment with an irreversible EGFR tyrosine kinase inhibitor (TKI). These studies support clinical testing of mTOR inhibitors in order to prevent the development and progression of EGFR mutant lung cancers.

Original languageEnglish (US)
Pages (from-to)1824-1832
Number of pages9
JournalCell Reports
Volume7
Issue number6
DOIs
StatePublished - Jun 26 2014
Externally publishedYes

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology

Fingerprint

Dive into the research topics of 'Rapamycin Prevents the Development and Progression of Mutant Epidermal Growth Factor Receptor Lung Tumors with the Acquired Resistance Mutation T790M'. Together they form a unique fingerprint.

Cite this